From Seekingalpha · SA Transcripts · · 40s
Orexo Q3 2026 Earnings Call Highlights
Orexo AB reports progress on FDA submission and clinical trial approvals for key products.
In brief
Orexo AB reports progress on FDA submission and clinical trial approvals for key products. Orexo AB achieved FDA submission for Izipry and IND acceptance for OX640, advancing its transformation into a platform-focused company. Originally reported by Seekingalpha.
Q3 2026 Earnings Report
Orexo AB presented Q3 2026 earnings with CEO Nikolaj Sørensen and CFO Frederik Jarrsten.
FDA Submission for Izipry
Orexo resubmitted Izipry to FDA on September 29 for a 6-month review ending in Q1 2027.
OX640 Clinical Trial Progress
Orexo received IND acceptance for OX640, confirming its clinical trial program for the quarter.
What it means
Orexo AB achieved FDA submission for Izipry and IND acceptance for OX640, advancing its transformation into a platform-focused company.
/i.s3.glbimg.com/v1/AUTH_63b422c2caee4269b8b34177e8876b93/internal_photos/bs/2026/W/a/tqIhseRHCeh4vsNHzovw/foto30pol-101-governa-a14.jpg)
/i.s3.glbimg.com/v1/AUTH_37554604729d4b2f9f3eb9ad8a691345/internal_photos/bs/2026/1/d/e0tBuBQiaj5t0cdmXHUA/foto29emp-301-vivenda-b7.jpg)
